Gadolinium Chloride Rescues Niemann–Pick Type C Liver Damage
AbstractNiemann–Pick type C (NPC) disease is a rare neurovisceral cholesterol storage disorder that arises from loss of function mutations in the NPC1 or NPC2 genes. Soon after birth, some patients present with an aggressive hepatosplenomegaly and cholestatic signs. Histopathologically, the liver presents with large numbers of foam cells; however, their role in disease pathogenesis has not been explored in depth. Here, we studied the consequences of gadolinium chloride (GdCl3) treatment, a well-known Kupffer/foam cell inhibitor, at late stages of NPC liver disease and compared it with NPC1 genetic rescue in hepatocytes in vivo. GdCl3 treatment successfully blocked the endocytic capacity of hepatic Kupffer/foam measured by India ink endocytosis, decreased the levels CD68—A marker of Kupffer cells in the liver—and normalized the transaminase levels in serum of NPC mice to a similar extent to those obtained by genetic Npc1 rescue of liver cells. Gadolinium salts are widely used as magnetic resonance imaging (MRI) contrasts. This study opens the possibility of targeting foam cells with gadolinium or by other means for improving NPC liver disease. Synopsis: Gadolinium chloride can effectively rescue some parameters of liver dysfunction in NPC mice and its potential use in patients should be carefully evaluated. View Full-Text
Share & Cite This Article
Klein, A.D.; Oyarzún, J.E.; Cortez, C.; Zanlungo, S. Gadolinium Chloride Rescues Niemann–Pick Type C Liver Damage. Int. J. Mol. Sci. 2018, 19, 3599.
Klein AD, Oyarzún JE, Cortez C, Zanlungo S. Gadolinium Chloride Rescues Niemann–Pick Type C Liver Damage. International Journal of Molecular Sciences. 2018; 19(11):3599.Chicago/Turabian Style
Klein, Andrés D.; Oyarzún, Juan E.; Cortez, Cristian; Zanlungo, Silvana. 2018. "Gadolinium Chloride Rescues Niemann–Pick Type C Liver Damage." Int. J. Mol. Sci. 19, no. 11: 3599.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.